Pulmonary inflammatory pathways

Pulmonary inflammatory pathways encompass the complex, multi-cellular signaling networks that coordinate the lung's response to injury, infection, or allergens (Barnes, 2017, Nature Reviews Immunology). These pathways involve a diverse array of molecular components, including cytokines (such as IL-4, IL-5, and TNF-alpha), chemokines, and lipid mediators like leukotrienes, which act on specific receptors to recruit and activate immune cells like eosinophils and neutrophils (Fahy, 2015, Nature Reviews Immunology). In chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), these pathways are pathologically sustained, leading to chronic airway inflammation, mucus overproduction, and structural remodeling of the lung tissue (Chung, 2015, European Respiratory Review). Therapeutic strategies often focus on inhibiting specific nodes within these pathways; for instance, corticosteroids provide broad anti-inflammatory effects by suppressing the transcription of pro-inflammatory genes, while biologics like monoclonal antibodies target specific cytokines or their receptors to provide more precise control (Wenzel, 2012, Nature Medicine). Understanding these pathways is crucial for developing personalized medicine approaches, where biomarkers like eosinophil counts or FeNO levels are used to select the most appropriate targeted therapy for individual patients (StatPearls, 2023).

Other names

Airway inflammatory pathwaysLung inflammation signalingRespiratory inflammatory cascades

Therapeutic agents modulate these pathways by inhibiting pro-inflammatory mediators, blocking cell surface receptors, or interfering with intracellular signaling cascades to reduce airway inflammation and improve lung function.